Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov 18:3:676.
doi: 10.1186/2193-1801-3-676. eCollection 2014.

Strontium ranelate effect on bone mineral density is modified by previous bisphosphonate treatment

Lucas R Brun  1 , Ana M Galich  2 , Eduardo Vega  3 , Helena Salerni  4 , Laura Maffei  5 , Valeria Premrou  5 , Pablo R Costanzo  4 , Marcelo A Sarli  6 , Paula Rey  6 , María S Larroudé  7 , María S Moggia  8 , María L Brance  9 , Ariel Sánchez  10 ; Grupo Argentino de Estudio del Ranelato de Estroncio (GAERE)
Affiliations

Strontium ranelate effect on bone mineral density is modified by previous bisphosphonate treatment

Lucas R Brun et al. Springerplus. .

Abstract

The aim of this study was to evaluate the effect of strontium ranelate (SrR) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of SrR in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 482 postmenopausal women treated with SrR (2 g/day) for 1 year in ten Argentine centers; 41 patients were excluded due to insufficient data, while 441 were included. Participants were divided according to previous bisphosphonate treatment in two groups: BP-naïve (n = 87) and BP-prior (n = 350). Data are expressed as mean ± SEM. After 1 year of treatment with SrR the bone formation markers total alkaline phosphatase and osteocalcin were increased (p < 0.0001), while the bone resorption marker s-CTX was decreased (p = 0.0579). Also increases in BMD at the lumbar spine (LS, 3.73%), femoral neck (FN, 2.00%) and total hip (TH, 1.54%) [p < 0.0001] were observed. These increments were significant (p < 0.0001) both among BP-naïve and BP-prior patients. Interestingly, the change in BMD after 1 year of SrR treatment was higher in BP-naïve patients: LS: BP-naïve = 4.58 ± 0.62%; BP-prior = 3.45 ± 0.28% (p = 0.078). FN: BP-naïve = 2.79 ± 0.56%; BP-prior = 2.13 ± 0.29% (p = 0.161). TH: BP-naïve = 3.01 ± 0.55%; BP-prior = 1.22 ± 0.27% (p = 0.0006). SrR treatment increased BMD and bone formation markers and decreased a bone resorption marker in the whole group, with better response in BP-naïve patients.

Keywords: Bisphosphonate-naïve; Bone mineral density; Strontium ranelate.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Increase of bone formation markers and decrease of a bone resorption marker after 1 year of treatment with SrR (*p < 0.05 vs basal).
Figure 2
Figure 2
BMD increase at all sites after 1 year of treatment with SrR (*p < 0.05 vs basal).
Figure 3
Figure 3
A better response in BP-naïve patients was observed after 1 year of treatment with SrR (*p < 0.05 vs basal).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Arlot ME, Jiang Y, Genant HK, Zhao J, Burt-Pichat B, Roux JP, Delmas PD, Meunier PJ. Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res. 2008;23:215–222. doi: 10.1359/jbmr.071012. - DOI - PubMed
    1. Atkins GJ, Welldon KJ, Halbout P, Findlay DM. Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int. 2009;20:653–664. doi: 10.1007/s00198-008-0728-6. - DOI - PubMed
    1. Bonnelye E, Chabadel A, Saltel F, Jurdic P. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone. 2008;42:129–138. doi: 10.1016/j.bone.2007.08.043. - DOI - PubMed
    1. Brennan TC, Rybchyn MS, Green W, Atwa S, Conigrave AD, Mason RS. Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol. 2009;157:1291–1300. doi: 10.1111/j.1476-5381.2009.00305.x. - DOI - PMC - PubMed
    1. Busse B, Jobke B, Hahn M, Priemel M, Niecke M, Seitz S, Zustin J, Semler J, Amling M. Effects of strontium ranelate administration on bisphosphonate-altered hydroxyapatite: Matrix incorporation of strontium is accompanied by changes in mineralization and microstructure. Acta Biomater. 2010;6:4513–4521. doi: 10.1016/j.actbio.2010.07.019. - DOI - PubMed

LinkOut - more resources